Navigation Links
Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
Date:4/28/2011

SAN DIEGO, April 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that additional data from the DIFICID™ Phase 3 trials will be presented at the following medical meetings:Digestive Disease Week (DDW), McCormick Place, Chicago, ILMay 7-10, 2011Poster Presentation Information:Title:

Risk of Recurrence and Time to Recurrence Following Treatment of Clostridium difficile Infection: Patient Characteristics and the Differential Effect of Fidaxomicin vs. VancomycinPresenter:

Kathleen M. Mullane, D.O.Date:

Saturday, May 7, 2011 Time:

12:00 p.m. to 2:00 p.m. Central TimeLocation:

Poster Session Hall A (MCP)Session:

Intestinal Disorders: Prebiotics, Probiotics and PathogensProgram #:

Sa1981Poster Presentation Information:Title:

High Fecal and Low Plasma Levels of Fidaxomicin and Metabolite OP-1118 inPatients with C. difficile infection:  Combined Results of Two Phase 3 TrialsPresenter:

Pamela S. Sears, Ph.D. Date:

Monday, May 9, 2011 Time:

12:00 p.m. to 2:00 p.m. Central TimeLocation:

Poster Session Hall A (MCP)Session:

Randomized Controlled Clinical TrialsProgram #:

Mo1160European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy, Milano Convention Center, Milan, ItalyMay 7-10, 2011 Oral Presentation Information:Title:

Immunosuppression and the Risk of Death, Cure Rates and Disease RecurrenceAmong Patients with Clostridium difficile InfectionPresenter:

Yoav Golan, M.D., M.S.Date:

Tuesday, May 10, 2011 Time:

10:36 a.m. to 10:48 a.m. Central European TimeLocation:

Lecture Hall Brown 1Oral Session:

C. difficile NewsPresentation #:

O504Poster Presentation Information:Title:

Cl
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (PRWEB) June 18, 2013 ActiGraph, a ... solutions for the global research community, announced today that ... Board. Dr. Matsudo is the Scientific Director of the ... (CELAFISCS), a Professor of Medicine at Gama Filho University ... organized by the State Secretariat of Health of São ...
(Date:6/18/2013)... NuView Life Sciences (NLS), a privately ... diagnostic (IVD) biomarkers, today announced the results from a ... development for the early detection of Prostate and Bladder ... presentation at the 2013 Annual Meeting of the Society ... Canada on Sunday, June 9th. NLS acquired the ...
(Date:6/17/2013)... NASA deployed an improved Air ... monitor potentially harmful chemicals in the air on the ... by Draper Laboratory , is currently being used ... that is processed and re-circulated within the spacecraft or ... even in trace amounts, endangers their health. Harmful compounds ...
(Date:6/17/2013)... As a leader in the skincare industry, the team ... for acne, rosacea, and eczema. As part of Acne and ... Rosacea Society) has dedicated a month to creating awareness about ... on treatment options. Probiotic Action follows in the footsteps of ... via social networks and online resources for the acne and ...
Breaking Biology Technology:Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board 2NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 2NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 3New Monitoring System Will Better Protect NASA Astronauts on ISS 2Acne and Rosacea Awareness Month: Probiotic Action Announces their Daily News Updates with Insight on the Most Common Skin Conditions 2
... in the Materials Science and Technology division of ... injection, detection and precession of spin accumulation in ... at temperatures up to 225 degrees Celsius. These ... in Si is viable as a basis for ...
... 5, 2011 Codexis, Inc. (NASDAQ: CDXS ) ... 31, 2011.   First Quarter Financial Highlights:Revenue: ... of $31.0 million, an increase of 21% from $25.7 million ... million increased 106% over the same time period driven by ...
... 2011 In parts of the world where dengue fever ... is a waste not only of time and money. It ... infection called chikungunya—its high fever, joint pain that can last ... of dengue. Recovery from the acute phase of the infection ...
Cached Biology Technology:NRL scientists achieve high temperature milestone in silicon spintronics 2NRL scientists achieve high temperature milestone in silicon spintronics 3Codexis Reports First Quarter 2011 Results 2Codexis Reports First Quarter 2011 Results 3Codexis Reports First Quarter 2011 Results 4Codexis Reports First Quarter 2011 Results 5Codexis Reports First Quarter 2011 Results 6Codexis Reports First Quarter 2011 Results 7SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus 2SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus 3
(Date:6/17/2013)... Research Foundation and Horizon Pharma further establish their commitment ... 2013 AGA-Horizon Pharma Fellow Abstract Prizes and the 2013 ... year, this competition continues to grow in popularity among ... basic and clinical research," said Nicholas F. LaRusso, MD, ... extremely proud of all that these fellows and students ...
(Date:6/17/2013)... A new study ... can be reversed with treatment. The study by researchers from ... McGill University and at Universit de Montral found that blocking ... mice with advanced Alzheimer,s disease (AD) recovers memory and cerebrovascular ... in May, also suggest an underlying mechanism of AD ...
(Date:6/16/2013)... triggered a similar marine ecosystem crisis to those witnessed ... according to research published today in Nature Geoscience ... of Newcastle, UK, Cologne, Frankfurt and GEOMAR-Kiel, confirms the ... marine ecosystem during the mid-Cretaceous greenhouse period. ... and duration of the temperature change.,Analysing the geochemistry and ...
Breaking Biology News(10 mins):Horizon Pharma Abstract Prizes recognize promising fellows and students 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2Global cooling as significant as global warming 2
... a specific mutation of the COX2 gene seems to ... increasing womens susceptibility to developing the disease. The ... confirmed by further studies, it might be possible to ... ibuprofen, which are used already for other conditions, to ...
... have found evidence that supports the theory that reproductive ... at the level of sperm cell motility. In a ... Society Interface, a team led by Michael Berns, an ... of biomedical engineering at the Beckman Laser Institute ...
... sequencing technology that can in one fell swoop decode 50 ... a research team led by University of Delaware scientists is ... switched on or off in rice--a crop vital to the ... which is supported by a $5.3-million grant from the National ...
Cached Biology News:Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 2Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 3Primate sperm competition: speed matters 2UD leads $5.3-million research project on rice epigenetics 2UD leads $5.3-million research project on rice epigenetics 3UD leads $5.3-million research project on rice epigenetics 4
iEMS Thermal Microplate Holder...
...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... oligonucleotides: PTOs are internucleotide modifications, ... backbone is replaced by a sulphur atom. ... degradation. PTOs are available as ... Oligonucleotides with thio-caps ...
Biology Products: